VEGF: A consistent target for antitumor therapy

Pathologists first observed several cases of an abnormal increase in vascularization of human tumors more than a century ago. Ide et al. were the first to postulate the existence of vascular growth-stimulating factors produced by tumor cells to support oncogenesis in relation to these phenomena.

VEGF: A consistent target for antitumor therapy

Image Credit: ACROBiosystems

Dr. Judah Folkman first suggested the new notion of preventing tumor angiogenesis as a possible method of treating cancer and other malignancies in 1971. However, it was not until 1983 that vascular endothelial growth factor (VEGF), a factor that increased vascular permeability and was relevant to tumor angiogenesis, was identified.

VEGF is an important regulator of angiogenesis in embryonic development, skeletal growth, and reproductive function and has been implicated in pathological angiogenesis associated with tumors, intraocular neovascular diseases, and other diseases.

Despite being discovered in 1983, the Pharma Projects database still places VEGF among the top five after Her-2, EGFR, CD3E, and CD19.

Due to the crucial role that VEGF plays in controlling both physiological and pathological angiogenesis, it has become an “inspiring” target for both existing and novel drugsover the past two decades.

VEGF family: Ligands and receptors

Understanding the diverse functions of VEGF in physiologic processes is essential for comprehending the implications and potential of VEGF as a therapeutic target. The placental growth factor (PIGF) with three tyrosine kinase receptors, VEGFR-1, VEGFR-2, and VEGFR-3, and five primary subtypes, VEGF-A, VEGF-B, VEGF-C, and VEGF-D, make up the complicated VEGF signaling system.

While all subtypes have some degree of homology to VEGF, the original VEGF refers primarily to VEGF-A, which is essential for angiogenesis and maintenance. There are several isoforms of VEGF-A, including VEGF121, VEGF165, VEGF189, and VEGF206. Each isoform has unique molecular characteristics, with VEGF165 being the most prevalent and has the best bioavailability and biopotency.

VEGF: A consistent target for antitumor therapy

Interaction of VEGF with receptors. Image Credit: ACROBiosystems

There are variations among VEGF receptors in terms of their selectivity and affinities to various ligands. The majority of biological responses to VEGF are known to be mediated by VEGFR-2, which also plays a significant role in angiogenesis, microvascular permeability, and endothelial cell mitosis and survival.

The role of VEGF in tumors

The physiological mechanisms of angiogenesis and microvascular permeability affect the development of blood vessels from pre-existing capillaries. These crucial mechanisms for embryonic development and adult wound healing are mediated by VEGF and its receptors. However, this signaling system is altered to promote the growth of tumors.

VEGF is increased during oncogenesis by oncogene expression, a number of growth factors, and hypoxia. The growth factor VEGF, together with other growth factors released by the tumor, activates the angiogenic switch, causing new blood vessels to develop around the tumor and promoting exponential growth.

The resulting blood vessels are bent, uneven in shape, and lack venules, arterioles, and capillaries because of the aberrant rise in angiogenesis. Additionally, these veins bleed and leak, which raises interstitial pressure close to the tumor. Due to the inadequate blood flow caused by these abnormal arteries, hypoxia is exacerbated, which leads to increased VEGF synthesis and, eventually, angiogenesis.

Representative drugs targeting VEGF in progress

VEGF is a potent target for anticancer therapy due to the crucial role it plays in tumor angiogenesis. Monoclonal and bispecific antibodies (bsAb) that target VEGF are currently the focus of a growing number of businesses. Three typical VEGF-targeting drugs are highlighted below.

A humanized anti-VEGF IgG1 monoclonal antibody called bevacizumab was created by Roche and is the first anti-angiogenic drug approved for treatment in a range of tumor types. By directly attaching to VEGF, the antibody blocks tumor-initiated angiogenesis, which in turn stops the spread and development of the tumor.

For the treatment of metastatic colorectal cancer, bevacizumab was licensed by the FDA in 2004, recognized in Europe in 2005, and introduced in China in 2010. The drug was authorized in 2015 to treat non-small cell lung cancer.

Currently, non-small cell lung cancer, colorectal cancer, renal cell carcinoma, glioblastoma, cervical cancer, fallopian tube cancer, ovarian cancer, peritoneal cancer, and many other types of cancer are among the approved indications of use.

VEGF: A consistent target for antitumor therapy

Mechanism of action of bevacizumab. Image Credit: ACROBiosystems

Akeso’s PD-1/VEGF bsAb (AK112), which is based on the company’s distinctive TETRABODY technology, is one of the well-known drugs. This drug is now being tested in patients as a PD-1 antibody and VEGF blocker combination therapy for a variety of tumor types, such as non-small cell lung cancer, renal cell carcinoma, and hepatocellular carcinoma.

Since AK112 simultaneously blocks two targets, it can function more efficiently than a single agent, resulting in increased antitumor activity.

VEGF: A consistent target for antitumor therapy

Mechanism of action of AK112. Image Credit: ACROBiosystems

Roche also has a bsAB drug named Faricimab that targets Ang-2 and VEGF-A for use in ophthalmic diseases. There is currently little information available, but Roche has claimed that this drug may be used to treat diabetic macular edema and neovascular age-related macular degeneration (nAMD) (DME).

VEGF: A consistent target for antitumor therapy

Structure of Faricimab. Image Credit: ACROBiosystems

To sum up, VEGF has been implicated in a variety of human cancers as an underlying facilitator for tumorigenesis and disease development. A treatment plan that targets VEGF/VEGFR offers a special entry point into the tumor’s vascular microenvironment.

As a result, VEGF possesses a variety of traits that make it a desirable target for prospective therapies. The vascular microenvironment surrounding the tumor serves as the entry point for the targeted therapeutic method that targets VEGF/VEGFR.

The permeability of tumor drugs can also enhance their anti-tumor impact. On one hand, it can cut off the nutritional source of tumor cells and prevent tumor growth; On the other hand, the anti-tumor effect can be enhanced by the permeability of tumor drugs.

To aid in the development of VEGF/VEGFR antibody medicines, ACROBiosystems has introduced a range of HEK293-expressed VEGF family proteins with high purity, multi-species, multi-tags, and highly bioactive VEGF family proteins.

Product list

Source: ACROBiosystems

Molecule Cat. No. Species Product Description
VEGF165 VE5-H4210 Human ActiveMax® Human VEGF165 Protein, Tag Free (MALS verified)HOT
VE5-H5248 Human VEGF165 Protein, His TagHOT
VE5-H8210 Biotinylated Human VEGF165, epitope tag free, ultra sensitivity (primary amine labeling)HOT
VE5-H82Q0 Biotinylated Human VEGF165 Protein, His, AvitagHOT
VE5-HF248 FITC-Labeled Human VEGF165 Protein, His TagHOT
VEGF121 VE1-H4213 ActiveMax® Human VEGF121 Protein, Tag FreeHOT
VE1-H5246 Human VEGF121 Protein, His Tag (MALS verified)HOT
VE1-H82E7 Biotinylated Human VEGF121 Protein, Avitag, His TagHOT
VEGF110 VE0-H5212 ActiveMax® Human VEGF110 Protein, Tag Free (HPLC-verified)
VEGF120 VE0-M4211 Mouse ActiveMax® Mouse VEGF120 Protein, Tag Free
VE0-M82Q2 Biotinylated Mouse VEGF120 Protein, His, Avitag
VEGF164 VE4-M4216 ActiveMax® Mouse VEGF164 Protein, Tag Free (HPLC-verified)
VE4-M82Q3 Biotinylated Mouse VEGF164 Protein, His, Avitag
VEGF-C VEC-H4225 Human Human VEGF-C / Flt4-L Protein, His TagHOT
VEGF-D VED-H5228 Human Human VEGF-D Protein, His Tag
VEGF R1 VE1-H5220 Human Human VEGF R1 / Flt-1 Protein, His Tag
VE1-H82E3 Human Biotinylated Human VEGF R1 / Flt-1 Protein, His, Avitag
VE1-M5256 Mouse Mouse VEGF R1 / Flt-1 Protein, Mouse IgG2a Fc Tag, low endotoxin
VE1-R5257 Rhesus macaque Rhesus macaque VEGF R1 / Flt-1 Protein, Mouse IgG2a Fc Tag, low endotoxin
VEGF R2 KDR-H5227 Human Human VEGF R2 / KDR Protein, His Tag (MALS verified)
KDR-H5280 Human VEGF R2 / KDR Protein, Strep Tag (MALS verified)
KDR-H82E5 Biotinylated Human VEGF R2 / KDR Protein, Avitag, His Tag
VE2-C52H3 Rhesus macaque Rhesus macaque VEGF R2 / KDR Protein, His Tag
VE2-H5255 Human Human VEGF R2 / KDR Protein, Fc Tag
VE2-HF254 FITC-Labeled Human VEGF R2 / KDR Protein, His Tag
VE2-M5258 Mouse Mouse VEGF R2 / KDR Protein, Mouse IgG2a Fc Tag, low endotoxin
VEGF R3 FL4-H5251 Human Human VEGF R3 / FLT4 Protein, Fc Tag (MALS verified)
FL4-H82E1 Biotinylated Human VEGF R3 / FLT4 Protein, His, Avitag
FL4-M5251 Mouse Mouse VEGF R3 / FLT4 Protein, Mouse IgG2a Fc Tag, low endotoxin

 

Product features and verification data

VEGF: A consistent target for antitumor therapy

Image Credit: ACROBiosystems

High purity and homogeneous structure verified by SDS-PAGE and SEC-MALS

(Note: Native VEGF is a 45 kDa heparin-binding glycoprotein with a homodimer structure, the correct and homogeneous structure is significant to decrease the risk of drug development.)

VEGF: A consistent target for antitumor therapy

ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 98%. The purity of ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) is more than 95% in HP-SEC, and the molecular weight of this protein is around 40–55 kDa verified by SEC-MALS. Image Credit: ACROBiosystems

High biological activity verified by ELISA

VEGF: A consistent target for antitumor therapy

Immobilized Human VEGF121, His Tag (Cat. No.VE1-H5246) at 1 μg/mL (100 μL/well) can bind Human VEGFR1/R2, Fc Tag with a linear range of 0.4-6 ng/mL (QC tested). Image Credit: ACROBiosystems

High biological activity verified by SPR

VEGF: A consistent target for antitumor therapy

Avastin (Bevacizumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human VEGF165 Protein, His Tag (Cat. No. VE5-H5248) with an affinity constant of 1.03 nM as determined in a SPR assay (Biacore T200). Image Credit: ACROBiosystems

High biological activity verified by cell-based assay

VEGF: A consistent target for antitumor therapy

Inhibition assay shows that the proliferation effect of ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) is inhibited by increasing concentration of anti-VEGF mAb (Avastin). The concentration of VEGF165 used is 20 ng/mL. The ED50 is 0.065-0.229 μg/Ml. Image Credit: ACROBiosystems

VEGF: A consistent target for antitumor therapy

Image Credit: ACROBiosystems

References

  1. Napoleone Ferrara, Hans-Peter Gerber, et al. The biology of VEGF and its receptors. Nature Medicine. 2003, 9(6): 669–676.
  2. Peter Carmeliet. VEGF as a Key Mediator of Angiogenesis in Cancer. Oncology 2005;69 (suppl 3):4–10.
  3. Jayashree Sahni, Sunil S. Patel, et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema. American Academy of Ophthalmology. 2019: 1155–1170.

About ACROBiosystems

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control, and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.

To respond to the coronavirus pandemic, ACROBiosystems has developed SARS-CoV-2 antigens specifically designed and optimized for serological test kits, including Spike-derived antigen S1, RBD, and Nucleocapsid protein. Proteins have been supplied to diagnostic companies in large quantities.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Aug 30, 2022 at 4:24 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2022, August 30). VEGF: A consistent target for antitumor therapy. News-Medical. Retrieved on October 05, 2022 from https://www.news-medical.net/whitepaper/20220830/VEGF-A-consistent-target-for-antitumor-therapy.aspx.

  • MLA

    ACROBiosystems. "VEGF: A consistent target for antitumor therapy". News-Medical. 05 October 2022. <https://www.news-medical.net/whitepaper/20220830/VEGF-A-consistent-target-for-antitumor-therapy.aspx>.

  • Chicago

    ACROBiosystems. "VEGF: A consistent target for antitumor therapy". News-Medical. https://www.news-medical.net/whitepaper/20220830/VEGF-A-consistent-target-for-antitumor-therapy.aspx. (accessed October 05, 2022).

  • Harvard

    ACROBiosystems. 2022. VEGF: A consistent target for antitumor therapy. News-Medical, viewed 05 October 2022, https://www.news-medical.net/whitepaper/20220830/VEGF-A-consistent-target-for-antitumor-therapy.aspx.

Other White Papers by this Supplier